(Q36536707)

14 August 2017

1 reference

title

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective (English)

1 reference

14 August 2017

1 reference

Tack J

1

1 reference

14 August 2017

Fried M

2

1 reference

14 August 2017

Houghton LA

3

1 reference

14 August 2017

Spicak J

4

1 reference

14 August 2017

Fisher G

5

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Alimentary Pharmacology & Therapeutics

14 August 2017

published in

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

183-205

1 reference

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

The economic consequences of irritable bowel syndrome: a US employer perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Irritable bowel syndrome in Germany. A cost of illness study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Irritable bowel syndrome in France: a common, debilitating and costly disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A three-part controlled study of trimebutine in the treatment of irritable colon syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Meta-analysis: The treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Wheat fibre and irritable bowel syndrome. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Irritable colon and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Alosetron and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Benefit-risk assessment of tegaserod in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A comparison of psychological and medical treatment of the irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

The treatment of irritable bowel syndrome with hypnotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Self-management for women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02938.X

10.1111/J.1365-2036.2006.02938.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference